---
title: "RSV Protection for Newborns in 2026: Maternal Vaccine vs. Nirsevimab, Explained"
date: 2026-11-17T23:30:00-05:00
author: Shang Salamante
canonical_url: "https://www.americordblood.com/articles/rsv-protection-newborns-maternal-vaccine-vs-nirsevimab-explained"
section: Articles
---
![Rsv protection for newborns in 2026 maternal vaccine vs nirsevimab explained](https://assets.americordblood.com/transforms/blogs/7495841/rsv-protection-for-newborns-in-2026-maternal-vaccine-vs-nirsevimab-explained_dcd4b851eab0fdc82c7554dc6e8ca81c.jpg)    [  Pregnancy &amp; Parenting  ](https://www.americordblood.com/articles/pregnancy-parenting) 

 10 Min Read 

 

# RSV Protection for Newborns in 2026: Maternal Vaccine vs. Nirsevimab, Explained

As of 2026, families have two proven ways to help protect newborns from severe RSV: a maternal RSV vaccine given at 32–36 weeks of pregnancy and a long-acting monoclonal antibody (nirsevimab) given to infants. Both reduce medically attended RSV illness and hospitalizations in early infancy, and your clinicians can help choose the right option based on timing, season, and health factors.

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants, and nearly all children are infected by age 2. Infants—especially under 6 months, preterm babies, and those with certain heart, lung, or immune conditions—are at highest risk for severe disease and hospitalization, particularly during fall and winter RSV seasons in most of the United States.

## Key Takeaways

- Two options prevent severe RSV in early infancy: maternal vaccination at 32–36 weeks’ gestation or infant nirsevimab after birth in the RSV season.
- Most families need only one option; if the maternal vaccine is given at least 14 days before delivery, nirsevimab is generally not needed for that infant.
- Maternal vaccine trials showed about 69% efficacy against severe RSV disease through 6 months; nirsevimab trials showed about 75% efficacy against medically attended RSV through 5 months.
- Timing is key: maternal vaccination must occur late in pregnancy and at least 14 days before birth; nirsevimab is given once to eligible infants entering or born during RSV season.
- Preterm infants, multiples, and certain high-risk infants are eligible for nirsevimab; dosing is weight-based for the first season.
- Side effects for both options are generally mild (injection site pain, fatigue or rash); serious reactions are rare.
- RSV seasons vary by geography, and occasional supply constraints may affect nirsevimab availability; plan with your OB-GYN and pediatrician before delivery.

## What is RSV, and why are newborns at highest risk for severe disease?

RSV is a common respiratory virus that can cause bronchiolitis and pneumonia, and infants—especially under 6 months—have the highest rates of severe illness and hospitalization. In the U.S., RSV activity typically peaks in fall and winter, when newborns are most vulnerable due to small airways and immature immune systems.

RSV infects nearly all children by age 2, but younger infants are more likely to develop lower respiratory tract infection that requires medical care. CDC surveillance shows most regions experience RSV surges between October and March, though timing varies by location, with some areas (such as parts of Alaska and tropical jurisdictions) seeing different seasonal patterns.

## What prevention options exist now: maternal RSV vaccination during pregnancy vs. infant nirsevimab?

As of 2026, two evidence-based options are available in the U.S.: a maternal RSV vaccine (Pfizer Abrysvo) given at 32–36 weeks of pregnancy, and nirsevimab (Beyfortus), a long-acting monoclonal antibody given to infants. Both aim to prevent severe RSV in early infancy but are delivered to different recipients at different times.

The maternal vaccine prompts the pregnant person to make RSV-specific antibodies that cross the placenta to the fetus before birth. Nirsevimab is a single intramuscular dose of laboratory-made RSV-neutralizing antibodies administered directly to the infant to provide passive protection during their first RSV season.

## How effective are these options, and how do they work to protect babies?

Maternal RSV vaccination at 32–36 weeks reduced severe RSV disease in infants by about 69% through 6 months and reduced RSV-related hospitalizations by about 57% in clinical trials. Nirsevimab reduced medically attended RSV lower respiratory tract infection by about 75% and reduced RSV hospitalizations by about 62% through roughly 5 months of follow-up in phase 3 trials.

Both strategies provide passive immunity. Maternal vaccination induces high levels of maternal antibodies that are transferred across the placenta in late pregnancy and protect the newborn immediately after birth. Nirsevimab delivers a ready-made monoclonal antibody with an extended half-life, circulating in the infant’s bloodstream to neutralize RSV during the highest-risk months.

## When should each be given, and who is eligible (including preterm infants and multiples)?

Maternal vaccination is recommended at 32–36 weeks’ gestation during RSV season, ideally at least 14 days before delivery to allow antibody transfer. Nirsevimab is recommended for most infants under 8 months who are born during or entering their first RSV season, with weight-based dosing, and certain high-risk children may receive it in their second season.

- Maternal RSV vaccine (pregnancy): Given once at 32–36 weeks’ gestation, seasonally (for most of the continental U.S., typically fall–winter); timing may vary in locations with different RSV circulation.
- Infant nirsevimab (first season): Given once to most infants younger than 8 months born during or entering RSV season. Dose is 50 mg if the baby weighs &lt;5 kg (11 lb) and 100 mg if ≥5 kg (11 lb).
- Infant nirsevimab (second season, 8–19 months): Recommended for certain high-risk children (e.g., chronic lung disease of prematurity, significant congenital heart disease, severe immunocompromise, and others per clinical guidance).
- Preterm infants: Eligibility is based on chronological age and weight, not gestational age; preterm infants under 8 months are recommended to receive nirsevimab if born during or entering season.
- Multiples (twins, triplets): One maternal vaccine dose in pregnancy provides antibodies to all fetuses; after birth, each infant is assessed individually for nirsevimab eligibility and dosed by weight.

## Can a baby receive both maternal vaccination and nirsevimab, and how do clinicians decide?

Most infants need only one option; if the maternal RSV vaccine was given at least 14 days before birth, nirsevimab is generally not indicated. Clinicians may recommend nirsevimab if the maternal vaccine was not given, was given less than 14 days before delivery, or if certain conditions could limit antibody transfer or increase infant risk.

Clinical scenarios that may favor nirsevimab despite maternal vaccination include maternal conditions that can reduce transplacental antibody transfer (for example, some immunodeficiencies) or complex infant factors (such as cardiopulmonary bypass) based on professional guidance. Shared decision-making considers gestational timing, local RSV season, infant health status, and product availability.

## What are the known side effects and safety considerations for mothers and babies?

Both options have generally mild, short-lived side effects; serious adverse events are rare. For the maternal vaccine, common effects include injection-site pain, fatigue, headache, and muscle aches; for nirsevimab, injection-site reactions and mild rash may occur.

Maternal vaccine safety: In clinical evaluation, there was a small numerical imbalance in preterm birth and hypertensive disorders of pregnancy that was not statistically significant; the approved use at 32–36 weeks aims to maximize benefit and minimize potential risk. Nirsevimab safety: Hypersensitivity reactions are uncommon; it can be coadministered with routine infant vaccines without affecting vaccine responses based on current guidance.

## How do seasonality, geography, and supply affect access—and what should parents plan for before delivery?

RSV timing varies by region, so the ideal window for maternal vaccination and infant nirsevimab depends on local seasonality. Availability of nirsevimab has varied, and planning ahead with your clinicians helps ensure timely protection for your baby.

- Know your local RSV season: Most U.S. regions peak in fall–winter; check local health department or CDC surveillance for timing.
- Plan maternal vaccination: If you will be 32–36 weeks pregnant during RSV season, ask your OB-GYN to schedule the vaccine so that it is given at least 14 days before your expected delivery.
- Coordinate infant care: If you are due during RSV season or your baby will be under 8 months when the season starts, ask your pediatrician about nirsevimab stocking, timing, and insurance coverage.
- Ask about programs: Nirsevimab is included in the Vaccines for Children (VFC) program for eligible families; coverage for both options follows ACIP/CDC recommendations, though processes can vary by practice.
- Monitor supply updates: During the 2023–24 season, some areas experienced nirsevimab shortages; clinicians may prioritize higher-risk infants if supplies are constrained.

## What questions should you ask your OB-GYN and pediatrician to choose the right strategy for your family?

A short, structured conversation with your OB-GYN and pediatrician can align timing, eligibility, and logistics before delivery. Use these questions to guide shared decision-making and ensure a plan is in place at birth.

- Will I be 32–36 weeks pregnant during our local RSV season, and when should I receive the maternal RSV vaccine to be at least 14 days before delivery?
- If I do not receive the maternal vaccine (or deliver less than 14 days after it), when and where can my baby receive nirsevimab?
- Is my baby likely to be high risk (for example, preterm birth, heart or lung conditions), and would that change our plan for nirsevimab in the first or second season?
- Does your practice stock nirsevimab, and how is it billed or covered (including Vaccines for Children eligibility, Medicaid, or private insurance)?
- Are there any local RSV trends or supply considerations we should know about as we plan?
- Can nirsevimab be given at the same visit as routine newborn or well-baby vaccines, and do we need a follow-up appointment?

## How do the maternal RSV vaccine and nirsevimab compare at a glance?

FeatureMaternal RSV vaccine (Abrysvo)Infant nirsevimab (Beyfortus)Who receives itPregnant person at 32–36 weeks’ gestationInfant (primarily under 8 months for first season; selected high-risk 8–19 months for second season)Primary goalProtect infant via transplacental antibodiesProtect infant via passive monoclonal antibodyWhen givenSeasonally, ideally ≥14 days before deliverySeasonally, once per eligible infant before or during RSV seasonEfficacy (trials)≈69% reduction in severe RSV through 6 months; ≈57% reduction in hospitalization≈75% reduction in medically attended RSV; ≈62% reduction in hospitalization through ~5 monthsDoseSingle standard adult doseSingle IM dose: 50 mg if &lt;5 kg; 100 mg if ≥5 kg (first season). Second season (eligible high risk): 200 mg total as two 100 mg injections.Common side effectsInjection-site pain, fatigue, headache, myalgia (usually mild)Injection-site reactions, mild rash (usually mild)Special notesNot needed each pregnancy seasonally if out of season; not useful after deliveryCan be given with routine vaccines; use chronological age and weight for dosingUse together?If given ≥14 days before birth, infant usually does not need nirsevimabRecommended if maternal vaccine not given or given &lt;14 days before delivery; clinician discretion for special cases

## Frequently Asked Questions

### If I’m due in summer, should I still get the maternal RSV vaccine?

In most U.S. regions, maternal RSV vaccination is offered seasonally when delivery is expected to occur during RSV season. If you will deliver outside your area’s season, your OB-GYN may not recommend the vaccine; instead, your pediatrician can plan for nirsevimab if your baby will be under 8 months when the next season begins.

### My baby was born preterm—does that change RSV protection recommendations?

Preterm infants under 8 months who are born during or entering RSV season are recommended to receive nirsevimab, with dosing based on actual weight. Preterm status also increases the likelihood of qualifying for a second-season dose in the 8–19 month window if other risk factors are present.

### Can nirsevimab be given with my baby’s routine vaccines?

Yes. Current guidance allows coadministration of nirsevimab with routine infant immunizations at the same visit without spacing. No significant interference with vaccine responses has been observed.

### What if I got the maternal vaccine but delivered less than 14 days later?

If delivery occurs within 14 days of maternal vaccination, most infants should still receive nirsevimab because there may not have been enough time for optimal antibody transfer. Your pediatrician can arrange dosing as soon as feasible during the season.

### Is nirsevimab covered by insurance or assistance programs?

Nirsevimab is included in the Vaccines for Children (VFC) program for eligible families, and many insurers cover it in line with CDC recommendations. Coverage and workflows can vary by practice, so ask your pediatrician’s office how they handle ordering and billing.

### Are there long-term safety concerns with these options?

Both options underwent large clinical evaluations with ongoing safety monitoring by FDA, CDC, and professional bodies. Most reported side effects are mild and short-lived; your clinicians will review benefits and any potential risks in the context of your pregnancy and your baby’s health.

## Sources

1. CDC — [RSV Immunization Guidance for Infants and Young Children (Nirsevimab)](https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html)
2. CDC — [RSV Vaccine Guidance for Pregnant People](https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html)
3. FDA — [FDA Approves First Vaccine for Use During Pregnancy to Prevent RSV Lower Respiratory Tract Disease in Infants](https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-use-during-pregnancy-prevent-rsv-lower-respiratory-tract-disease-infants)
4. NEJM — [Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants (MELODY Trial)](https://www.nejm.org/doi/full/10.1056/NEJMoa2110275)
5. CDC — [Use of the Pfizer RSV Vaccine During Pregnancy for the Prevention of RSV Illness in Infants — ACIP Recommendations, 2023](https://www.cdc.gov/mmwr/volumes/72/wr/mm7241e1.htm)
6. AAP — [Nirsevimab Frequently Asked Questions](https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-frequently-asked-questions/)
7. CDC — [National Respiratory and Enteric Virus Surveillance System (NREVSS) — RSV](https://www.cdc.gov/surveillance/nrevss/rsv/index.html)
8. CDC — [Health Alert Network (HAN): Limited Availability of Nirsevimab in the United States — 2023–2024 RSV Season](https://emergency.cdc.gov/han/2023/han00499.asp)

*The views, statements, and pricing expressed are deemed reliable as of the published date. Articles may not reflect current pricing, offerings, or recent innovations.*

 

  

### Complete Family Plan

Perfect for families who believe in the frontier of modern and regenerative medicine.

 [ View Service ](https://www.americordblood.com/complete-family-plan) 

### Simple, Straight Forward Pricing

At Americord, we provide the highest-quality stem cell processing and the lowest storage rates in the industry. Discover which payment plan is best for you!

 [ View Service ](https://www.americordblood.com/pricing) 

### Be the First to Know

Never miss the latest cord blood breakthrough, clinical trial, or stem cell education to keep your family healthy for life.

  Sign Up  

    

  

 

 

 

 

 Share [  ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.americordblood.com%2Farticles%2Frsv-protection-newborns-maternal-vaccine-vs-nirsevimab-explained "Facebook") [  ](https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.americordblood.com%2Farticles%2Frsv-protection-newborns-maternal-vaccine-vs-nirsevimab-explained "LinkedIn") [  ](mailto:?body=https%3A%2F%2Fwww.americordblood.com%2Farticles%2Frsv-protection-newborns-maternal-vaccine-vs-nirsevimab-explained "Email") 

 

  

## Related Articles

 [    ![6a7248f8a5e4d9396b8a04b5 1785876646180](https://assets.americordblood.com/transforms/blogs/6403757/6a7248f8a5e4d9396b8a04b5-1785876646180_41a4f2ed037c5ad51696884668d44cc6.jpg)  ](https://www.americordblood.com/articles/fall-immunity-guide-protecting-you-and-your-baby-this-autumn) [### Fall Immunity Guide: Protecting You and Your Baby This Autumn

 ](https://www.americordblood.com/articles/fall-immunity-guide-protecting-you-and-your-baby-this-autumn)

On-time vaccines, daily habits, and visitor rules to protect pregnant people and newborns from flu, COVID and RSV this fall.

 

 [ Read More ](https://www.americordblood.com/articles/fall-immunity-guide-protecting-you-and-your-baby-this-autumn) 

 

 [    ![Newborn baby smiling holding moms finger](https://assets.americordblood.com/transforms/blogs/3873269/newborn-baby-smiling-holding-moms-finger_41a4f2ed037c5ad51696884668d44cc6.jpg)  ](https://www.americordblood.com/articles/common-newborn-illnesses-to-know-about) [### Common Newborn Illnesses to Know About

 ](https://www.americordblood.com/articles/common-newborn-illnesses-to-know-about)

Learn about common newborn illnesses, their symptoms, and preventive measures to ensure your baby's health during the early days.

 

 [ Read More ](https://www.americordblood.com/articles/common-newborn-illnesses-to-know-about) 

 

 [    ![6a735194a5e4d9396b8a0ca6 1785944209735](https://assets.americordblood.com/transforms/blogs/6409410/6a735194a5e4d9396b8a0ca6-1785944209735_2026-08-06-154930_meqh_41a4f2ed037c5ad51696884668d44cc6.jpg)  ](https://www.americordblood.com/articles/sickness-in-the-house-protecting-your-pregnancy-from-school-aged-bugs) [### Sickness in the House: Protecting Your Pregnancy from School-Aged Bugs

 ](https://www.americordblood.com/articles/sickness-in-the-house-protecting-your-pregnancy-from-school-aged-bugs)

Simple, practical steps to lower infection risk during pregnancy when school-aged kids bring home bugs.

 

 [ Read More ](https://www.americordblood.com/articles/sickness-in-the-house-protecting-your-pregnancy-from-school-aged-bugs)
